Rockland Trust’s Biogen BIIB Stock Holding History

Rockland Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-808	Closed	-$257K	–	208
2017 Q4	$257K	Buy	+808	New	+$259K	0.03%	177

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rockland Trust's BIIB Position: Q1 2018 in Review

Rockland Trust sold out of Biogen (BIIB) in Q1 2018, closing a stake of 808 shares — an estimated $257K sold.

Rockland Trust first reported a position in BIIB in Q4 2017 and held it in 1 quarter. The position peaked at $257K in Q4 2017. 1,101 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Rockland Trust reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Rockland Trust sold 808 Biogen shares in Q1 2018, an estimated $257K.
Rockland Trust first reported a position in Biogen in Q4 2017 and held it in 1 quarter.
Rockland Trust's Biogen position peaked at $257K in Q4 2017.
1,101 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Rockland Trust's 13F filing for Q1 2018, filed 10 Apr 2018.